GlassScriptPhysician profile
Matteethra C Jacob
NPI 1417020744
$2,721.22
in general payments reported to CMS, 2019-2025
20 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $463 · 2021: $868 · 2022: $439 · 2023: $469 · 2024: $129 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.87 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $450.72 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $380.88 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $208.58 | 2023 | Optimizer |
| Novartis Pharmaceuticals Corporation | $195.00 | 2019-2025 | |
| Abbott Laboratories | $189.47 | 2021-2023 | Durata |
| Amgen INC. | $181.54 | 2019-2023 | Repatha |
| Arbor Pharmaceuticals, INC. | $120.78 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $81.18 | 2020-2025 | Eliquis |
| Pfizer INC. | $63.60 | 2020-2022 | |
| Novo Nordisk INC | $60.65 | 2024-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $41.31 | 2021 | |
| Lilly USA, LLC | $40.92 | 2021-2025 | Zepbound |
| Boston Scientific Corporation | $35.74 | 2020-2021 | |
| Edwards Lifesciences Corporation | $30.19 | 2023 | Sapien 3 Ultra Resilia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $27.82 | 2019 | |
| Itamar Medical INC | $25.52 | 2024 | Watchpatone |
| Astrazeneca Pharmaceuticals LP | $17.57 | 2023 | Farxiga |
| Cook Medical LLC | $13.96 | 2023 | Zilver Ptx |
| Allergan, INC. | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matteethra Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.